QDX Congratulates Co-Founder and Head of Research A/Prof. Giuseppe Barca on Receiving the 2025 Dirac Medal
SINGAPORE, May 8, 2025 /PRNewswire/ -- QDX proudly congratulates its Co-Founder and Head of Research, A/Prof. Giuseppe Barca, on being awarded the 2025 Dirac Medal, the highest international honour for early-career researchers in theoretical and computational chemistry.
Presented by the World Association of Theoretical and Computational Chemists (WATOC), the Dirac Medal recognises scientists under 40 whose research has made exceptional contributions to the field. A/Prof. Barca is recognised for his pioneering work in quantum algorithms and high-performance computing, which has advanced the frontiers of molecular simulation and accelerated applications in drug discovery.
"This is a phenomenal and well-deserved honour for Giuseppe," said Loong Wang, CEO of QDX. "His research continues to redefine what's possible in computational chemistry. This award not only celebrates his individual achievement but also reinforces the bold science that drives QDX."
In addition to his role at QDX, A/Prof. Barca leads the Barca Lab at both the Australian National University and the University of Melbourne, where he develops fast, scalable quantum chemistry methods and algorithms for next-generation computing platforms. His innovations form the core of Rush, QDX's proprietary AI-quantum platform designed to deliver high-precision molecular modelling at cloud scale.
As QDX continues to push the frontier of drug discovery with advanced computational tools, A/Prof. Barca's vision and leadership remain central to its mission to enable and accelerate the discovery of new therapies.
About QDX
QDX is a drug discovery company specializing in high-performance quantum simulations to accelerate the design of new therapeutics. Founded by experts in life science, computational chemistry, and high-performance computing, QDX collaborates with global partners to develop innovative solutions for complex diseases, aiming to transform the landscape of drug discovery. Its flagship platform, Rush, empowers biotech innovators to conduct fast, cost-effective molecular modeling, virtual screening, and predictive analytics—no installation or proprietary hardware required.
Media Contact:
PR Newswire Asia Ltd.
PR Newswire
1954年に設立された世界初の米国広報通信社です。配信ネットワークで全世界をカバーしています。Cision Ltd.の子会社として、Cisionクラウドベースコミュニケーション製品、世界最大のマルチチャネル、多文化コンテンツ普及ネットワークと包括的なワークフローツールおよびプラットフォームを組み合わせることで、様々な組織のストーリーを支えています。www.prnasia.com
本プレスリリースは発表元が入力した原稿をそのまま掲載しております。また、プレスリリースへのお問い合わせは発表元に直接お願いいたします。
プレスリリース添付画像
このプレスリリースには、報道機関向けの情報があります。
プレス会員登録を行うと、広報担当者の連絡先や、イベント・記者会見の情報など、報道機関だけに公開する情報が閲覧できるようになります。
